- ►chestpubs.org SR Salpeter, TM Ormiston, EE Salpeter - Chest, 2004 - chestjournal.chestpubs.org Background: β-Adrenergic agonists exert physiologic effects that are the
opposite of those of β-blockers. β-Blockers are known to reduce morbidity and
mortality in patients with cardiac disease. β 2 -Agonist use in patients ... Cited by 180 - Related articles - BL Direct - All 11 versions
MJ London, M Zaugg, MC Schaub, DR Spahn - Anesthesiology, 2004 - journals.lww.com THE recent focus on perioperative ß-adrenergic receptor blockade (PBB) to
reduce cardiac morbidity or mortality follows nearly 40 yr of research
documenting the car- dioprotective effects of ß-adrenergic receptors ... Cited by 109 - Related articles - BL Direct - All 5 versions
- ►bmj.com D Redelmeier, D Scales, A Kopp - British Medical Journal, 2005 - bmj.com You are seeing this message because your web browser does not support basic web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Objective To test whether ... Cited by 90 - Related articles - BL Direct - All 10 versions
- ►ahajournals.org A Auerbach, L Goldman - Circulation, 2006 - Am Heart Assoc Accurate estimation of a patient's risk for postoperative cardiac events (eg,
myocardial infarction, unstable angina, ventricular tachycardia, pulmonary
edema, and death) after noncardiac surgery can guide allocation of clinical ... Cited by 80 - Related articles - All 5 versions
SR Salpeter, TM Ormiston, EE Salpeter, PJ … - Respiratory medicine, 2003 - Elsevier Beta-blocker therapy has a mortality benefit in patients with hypertension,
heart failure and coronary artery disease, as well as during the perioperative
period. These drugs have traditionally been considered contraindicated in ... Cited by 67 - Related articles - All 8 versions
S Andreas, SD Anker, PD Scanlon, VK … - Chest, 2005 - chestjournal.chestpubs.org COPD is a major cause of death and disability worldwide. Treatment of COPD
improves lung function but is unlikely to slow the steady downhill course of the
disease or reduce mortality. In COPD, numerous abnormalities can be found ... Cited by 53 - Related articles - BL Direct - All 8 versions
MJ Reiter - Progress in cardiovascular diseases, 2004 - Elsevier Most of the important differences among agents reflect the relative specificity
for β 1 -, β 2 -, and α-adrenergic receptors. Selection of a particular agent
and target dose is probably best guided by available trial data, even ... Cited by 48 - Related articles - BL Direct - All 9 versions
- ►bmj.com K Amin, A Ekberg-Jansson, CG Lofdahl, P … - British Medical Journal, 2003 - thorax.bmj.com Methods: Bronchial biopsy specimens were taken from 29 smokers and 16 never
smokers and stained with monoclonal antibodies HNL, EPO, AA1, CD68 in order to
identify neutrophils, eosinophils, mast cells, and macrophages, ... Cited by 45 - Related articles - BL Direct - All 7 versions
- ►nih.gov Z Callaerts-Vegh, KLJ Evans, N Dudekula, D … - Proceedings of the National Academy of Sciences of …, 2004 - National Acad Sciences The clinical effects of treatment withn β-adrenoceptor (β-AR) agonists and
antagonists in heart failure vary with duration of therapy, as do the effects of
β-AR agonists in asthma. Therefore, we hypothesized that chronic effects ... Cited by 43 - Related articles - BL Direct - All 10 versions
